In the FIGHT-202 trial, the overall response rate (ORR) for pemigatinib was 35.5% in CCA patients with FGFR2 fusion or rearrangement, demonstrating superior efficacy compared to 0.0% in CCA patients without this genetic alteration. This evidence concerns the gene FGFR2 and cholangiocarcinoma.